For instance, trastuzumab is funded by all Canadian provinces for the adjuvant and palliative treatment of human epidermal growth factor receptor type 2 (her2/neu)–positive breast cancer, but bevacizumab is funded in only a few provinces for the palliative treatment of metastatic colorectal cancer. This evidence concerns the gene ERBB2 and breast carcinoma.